4 Undervalued Health Care Equipment & Supplies Stocks for Tuesday, October 29
Discover the top 4 undervalued Health Care Equipment & Supplies stocks for Tuesday, October 29 based on AAII’s Stock Grades.Tudor Pop
Stock Evaluator: Aethlon Medical, Inc. (AEMD)
Aethlon Medical, Inc. AEMD
$0.53
-0.03
-5.83%
July 31, 2026 9:30:01 AM
EST
Volume: 25,259
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation, and other disease states. The company was founded in 1984 and is based in San Diego, California.
Commentary & Analysis
3 Undervalued Advanced Medical Equipment & Technology Stocks for Thursday, September 12
Discover the top 3 undervalued Advanced Medical Equipment & Technology stocks for Thursday, September 12 based on AAII’s Stock Grades.Eunice Kim
3 Undervalued Advanced Medical Equipment & Technology Stocks for Thursday, June 13
Discover the top 3 undervalued Advanced Medical Equipment & Technology stocks for Thursday, June 13 based on AAII’s Stock Grades.Grace Malone
4 Undervalued Advanced Medical Equipment & Technology Stocks for Monday, May 13
Discover the top 4 undervalued Advanced Medical Equipment & Technology stocks for Monday, May 13 based on AAII’s Stock Grades.Jenna Brashear
3 Undervalued Advanced Medical Equipment & Technology Stocks for Thursday, June 15
Discover the top 3 undervalued Advanced Medical Equipment & Technology stocks for Thursday, June 15 based on AAII’s Stock Grades.Eunice Kim
Financial Summary
| Share Statistics | AEMD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1.3 | $334.8 | 1% |
|
| Shares Out (Mil) | 1.3 | 41.7 | 5% |
|
| Institutional Ownership | 90.3% | 77.3% | 58% |
|
| Float (Mil) | 2.4 | 34.7 | 6% |
|
| Beta | 1.32 | 0.86 | 76% |
|
| Avg Daily Volume (000s) | 65 | 266 | 31% |
|
| Price Change (52-week) |
(95.3%) | 60.7% | 2% |
|
| Growth | AEMD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 11.8% | na |
|
| Net Income (5yr) | 1.8% | (5.8%) | 42% |
|
| EPS (5yr) | 54.1% | 10.7% | 94 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (15.3%) | (16.1%) | 49% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 1 | 1 | |
| Current EPS | ($2.455) | ($10.400) | ($3.230) | |
| Month Ago EPS | ($2.455) | ($10.400) | ($3.230) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($2.455) | ($10.400) | ($0.980) | |
| Year/Year Chg | 64.3% | (2.0%) | (95.3%) | |
| Financials | AEMD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $152 | na |
|
| Net Income (TTM) (Mil) | ($7) | ($11) | 32% |
|
| EPS (TTM) | ($10.611) | ($0.500) | 4% |
|
| Operating Cash Flow (TTM) (Mil) | ($7) | ($2) | 22% |
|
| Net Cash Flow (TTM) (Mil) | na | $1 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $22 | 0% |
|
| Enterprise Value (Q1) (Mil) | $0 | $304 | 3% |
|
| Valuation | AEMD | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.18 | 2.88 | 3% |
|
| P/E | na | 30.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.9 | na |
|
| Ratios | AEMD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 59.1% | na |
|
| Net Margin | na | (7.7%) | na |
|
| ROA | (104.5%) | (13.7%) | 5% |
|
| ROE | (142.9%) | (15.9%) | 6% |
|
| Liabilities to Assets | 22.8% | 44.9% | 15% |
|
| F-Score | 4 | 4 | 34% |
|
Passing Stock Screens
As of 7/30/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Schloss Screen
Factors: Value, Quality
This screen looks for stocks hitting new lows, trading at a price lower than book value per share, with no debt and high levels of insider ownership.
| Performance Since Inception: | 1.2% |
| +/- S&P 500: | -6.3 |
